azeliragon (TTP488) / Cantex Pharma 
Welcome,         Profile    Billing    Logout  
 21 Diseases   6 Trials   6 Trials   141 News 


12»
  • ||||||||||  azeliragon (TTP488) / Cantex Pharma
    Journal:  Involvement of RAGE in radiation-induced acquisition of malignant phenotypes in human glioblastoma cells. (Pubmed Central) -  Jul 28, 2024   
    Both phenotypes were suppressed by specific inhibitors of RAGE (FPS-ZM1 and TTP488) or by knockdown of RAGE...In addition, ?-irradiation-induced phosphorylation of STAT3 was suppressed by RAGE inhibitors, and a STAT3 inhibitor suppressed ?-irradiation-induced enhancement of cell migration, indicating that STAT3 is involved in the migration enhancement downstream of RAGE. Our results suggest that HMGB1-RAGE-STAT3 signaling is involved in radiation-induced enhancement of GBM cell migration, and may contribute to GBM recurrence by promoting metastasis and invasion.
  • ||||||||||  azeliragon (TTP488) / Cantex Pharma
    Enrollment change, Trial completion date, Trial primary completion date, Metastases:  Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer (clinicaltrials.gov) -  Jun 13, 2024   
    P1/2,  N=30, Recruiting, 
    Our results suggest that HMGB1-RAGE-STAT3 signaling is involved in radiation-induced enhancement of GBM cell migration, and may contribute to GBM recurrence by promoting metastasis and invasion. N=18 --> 30 | Trial completion date: Nov 2024 --> May 2025 | Trial primary completion date: Oct 2024 --> Feb 2025
  • ||||||||||  Herceptin (trastuzumab) / Roche, azeliragon (TTP488) / Cantex Pharma, Perjeta (pertuzumab) / Roche
    RAGE inhibition to decrease cancer therapy related cardiotoxicity in women with early breast cancer (RAGE). (Hall A; Poster Bd #: 207a) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_1347;    
    P1/2
    In Cohort 4, 6 patients will receive dose dense doxorubicin and cyclophosphamide (ddAC)...As of 2/1/24, 4 patients have been enrolled, with 4 undergoing screening. At the completion of this trial, we plan a randomized trial to evaluate the role of TTP488 to decrease cardiotoxicity, cancer related cognitive decline and disease recurrence.
  • ||||||||||  azeliragon (TTP488) / Cantex Pharma
    Trial suspension:  Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma (clinicaltrials.gov) -  Feb 15, 2024   
    P1,  N=21, Suspended, 
    Our results provide novel insights into the role of the AGE-RAGE axis in skeletal muscle aging, and future work is warranted on the potential application of S100b as a pro-regenerative factor in aged skeletal muscle. Not yet recruiting --> Suspended
  • ||||||||||  azeliragon (TTP488) / Cantex Pharma
    Journal:  Macrophage RAGE activation is proinflammatory in NASH. (Pubmed Central) -  Jan 4, 2024   
    FFC mice that received a pharmacological inhibitor of RAGE (TTP488), and myeloid-specific RAGE KO mice (RAGE-MKO) had attenuated liver injury associated with a reduced accumulation of RAGE+ recruited macrophages...Correspondingly, the secretome of ligand-stimulated bone marrow derived macrophages from RAGE-MKO mice had an attenuated capacity to activate CD8+ T cells. Our data implicate RAGE as what we propose to be a novel and potentially targetable mediator of the proinflammatory signaling of recruited macrophages in NASH.
  • ||||||||||  azeliragon (TTP488) / Cantex Pharma
    Enrollment open:  Azeliragon in MGMT Unmethylated Glioblastoma (clinicaltrials.gov) -  Oct 27, 2023   
    P2,  N=30, Recruiting, 
    Our data implicate RAGE as what we propose to be a novel and potentially targetable mediator of the proinflammatory signaling of recruited macrophages in NASH. Not yet recruiting --> Recruiting
  • ||||||||||  azeliragon (TTP488) / Cantex Pharma
    Enrollment open, Trial initiation date:  Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma (clinicaltrials.gov) -  Sep 15, 2023   
    P1/2,  N=18, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Mar 2023 --> Sep 2023
  • ||||||||||  azeliragon (TTP488) / Cantex Pharma
    New P2 trial:  Azeliragon in MGMT Unmethylated Glioblastoma (clinicaltrials.gov) -  Aug 14, 2023   
    P2,  N=30, Not yet recruiting, 
  • ||||||||||  azeliragon (TTP488) / Cantex Pharma
    Journal:  RAGE inhibitor TTP488 (Azeliragon) suppresses metastasis in triple-negative breast cancer. (Pubmed Central) -  Jul 14, 2023   
    These results show that TTP488 impairs metastasis of TNBC and further clarifies the signaling and cellular mechanisms through which RAGE mediates metastasis. Importantly, as TTP488 displays a favorable safety profile in human studies, our study provides the rationale for evaluating TTP488 in clinical trials to treat or prevent metastatic TNBC.
  • ||||||||||  azeliragon (TTP488) / Cantex Pharma
    Review, Journal:  RAGE Inhibitors in Neurodegenerative Diseases. (Pubmed Central) -  May 16, 2023   
    Some of the RAGE antagonists, such as Azeliragon, are currently in clinical development for treating neurological diseases, including AD, although currently there have been no FDA-approved therapeutics based on the RAGE antagonists. This review outlines the AGE-RAGE interactions as a leading cause of the onset of neurological diseases and the current efforts on developing therapeutics for neurological diseases based on the RAGE antagonists.
  • ||||||||||  azeliragon (TTP488) / Cantex Pharma
    RAGE EXPRESSING MACROPHAGE SUBSETS MEDIATE INFLAMMATION IN NASH (South Hall A, Poster Hall - McCormick Place) -  Mar 23, 2023 - Abstract #DDW2023DDW_1520;    
    FFC-RLMC-KO and RAGE-i mice had significant attenuation of liver injury compared to FFC-WT and vehicle treated controls respectively, assessed by NAS-grading and ALT. Further, RLMC-KO mice had significantly lower RAGE expression by IHC of liver sections and fibrosis compared to FFC fed WT-mice.
  • ||||||||||  Enrollment open, Trial completion date, Trial primary completion date:  RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer (clinicaltrials.gov) -  Jan 9, 2023   
    P1/2,  N=48, Recruiting, 
    Further, RLMC-KO mice had significantly lower RAGE expression by IHC of liver sections and fibrosis compared to FFC fed WT-mice. Not yet recruiting --> Recruiting | Trial completion date: Nov 2023 --> Nov 2024 | Trial primary completion date: Nov 2023 --> Nov 2024
  • ||||||||||  Trial initiation date, Metastases:  RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer (clinicaltrials.gov) -  Sep 29, 2022   
    P1/2,  N=48, Not yet recruiting, 
    Importantly, as TTP488 displays a high safety profile in human trials, this study provides the rationale for evaluating TTP488 in clinical trials to treat or prevent metastatic breast cancer. Initiation date: Aug 2022 --> Nov 2022
  • ||||||||||  azeliragon (TTP488) / vTv Therapeutics
    Journal:  Design, synthesis and anti-TNBC activity of Azeliragon triazole analogues. (Pubmed Central) -  Jan 19, 2022   
    In order to develop a new anti-TNBC agent, we designed, synthesized and screened 26 Azeliragon triazole analogues to determine their anti-TNBC activities in vitro. The most active compound was KC-10 with an IC value of 0.220 ± 0.034 μM.
  • ||||||||||  Cilcane (cilengitide) / Iceni Pharma, azeliragon (TTP488) / vTv Therapeutics
    Journal:  RAGE and αVβ3-integrin are essential for suPAR signaling in podocytes. (Pubmed Central) -  Nov 17, 2021   
    The magnitude of this inhibition was indistinguishable from the effect produced by a neutralizing antibody against suPAR. These data suggest that orally bioavailable small molecule RAGE antagonists could represent a useful therapeutic strategy for a wide range of clinical conditions associated with elevated serum suPAR, including primary FSGS and AKI.
  • ||||||||||  azeliragon (TTP488) / vTv Therapeutics
    [VIRTUAL] RAGE DEPENDENT IRF SIGNALING IN MACROPHAGES IS PROINFLAMMATORY IN MOUSE AND HUMAN NASH () -  Oct 21, 2021 - Abstract #AASLD2021AASLD_2045;    
    In a diet induced mouse model of NASH, recruited macrophages repopulated the resident macrophage niche, and mediate liver inflammation via RAGE dependent upregulation of IRF5 and IRF7 and downstream inflammatory cytokine production. Our data implicate RAGE signaling as a novel and potentially targetable mediator of the proinflammatory phenotype of recruited macrophages in NASH .
  • ||||||||||  azeliragon (TTP488) / vTv Therapeutics
    Review, Journal:  Alzheimer's disease and type 2 diabetes mellitus: Pathophysiologic and pharmacotherapeutics links. (Pubmed Central) -  Jun 30, 2021   
    In this context, the hyperphosphorylation of tau and the formation of neurofibrillary tangles have been associated with the dysfunction of the phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways in the nervous tissues as well as the decrease in the expression of GLUT-1 and GLUT-3 in the different areas of the brain, increase in reactive oxygen species, and production of mitochondrial alterations that occur in T2DM. These findings have contributed to the implementation of overlapping pharmacological interventions based on the use of insulin and antidiabetic drugs, or, more recently, azeliragon, amylin, among others, which have shown possible beneficial effects in diabetic patients diagnosed with AD.
  • ||||||||||  azeliragon (TTP488) / vTv Therapeutics
    [VIRTUAL] SAFETY AND EFFICACY RESULTS FROM THE PHASE 2 ELEVAGE STUDY OF AZELIRAGON IN MILD ALZHEIMER’S DISEASE AND TYPE 2 DIABETES (On Demand Symposia D) -  Feb 19, 2021 - Abstract #ADPD2021ADPD_1583;    
    Consistent with previous studies, azeliragon was generally well‐ tolerated with similar incidences of treatment‐emergent adverse events overall and by system organ class (SOC) in both treatment groups.  Conclusions The study failed to meet its primary objective with no statistically significant treatment differences on the ADAS‐cog14 primary endpoint. Results for primary and secondary efficacy outcome measures, as well as safety measures, will be presented.
  • ||||||||||  azeliragon (TTP488) / Cantex Pharma
    Trial termination, Trial primary completion date:  Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance (clinicaltrials.gov) -  Feb 2, 2021   
    P2,  N=43, Terminated, 
    Results for primary and secondary efficacy outcome measures, as well as safety measures, will be presented. Active, not recruiting --> Terminated | Trial primary completion date: Apr 2020 --> Dec 2020; for business reasons
  • ||||||||||  azeliragon (TTP488) / Cantex Pharma
    Trial completion date, Trial primary completion date:  Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance (clinicaltrials.gov) -  Jan 5, 2021   
    P2,  N=43, Active, not recruiting, 
    Active, not recruiting --> Terminated | Trial primary completion date: Apr 2020 --> Dec 2020; for business reasons Trial completion date: Jul 2023 --> Feb 2021 | Trial primary completion date: Apr 2023 --> Apr 2020